Global Prostate Cancer Diagnostics Sales Market Report 2020

The prostate is a walnut-sized gland located behind the base of a man’s penis, in front of the rectum, and below the bladder. Cancer begins when healthy cells in the prostate change and grow out of control, forming a tumor. A tumor can be cancerous or benign. A cancerous tumor is malignant, meaning it can grow and spread to other parts of the body. A benign tumor means the tumor can grow but will not spread.
The classification of Prostate Cancer Diagnostics includes Tumor Biomarker Tests, Imaging, Biopsy and other, and most of Prostate Cancer Diagnostics use the method of Biopsy, the proportion of Biopsy in 2017 is about 44.65%.
Prostate Cancer Diagnostics is widely used for the people with Prostate Cancer, The most proportion of Prostate Cancer Diagnostics is used for people with the age between 55 and 75, and the proportion is about 70.24% in 2017.
North America region is the largest region of Prostate Cancer Diagnostics, with a revenue market share nearly 49.84% in 2017. Europe is the second region of Prostate Cancer Diagnostics, enjoying revenue market share nearly 28% in 2017.

Market Analysis and Insights: Global Prostate Cancer Diagnostics Market
The global Prostate Cancer Diagnostics market size is projected to reach US$ 19100 million by 2026, from US$ 12520 million in 2020, at a CAGR of 7.3% during 2021-2026.

Global Prostate Cancer Diagnostics Scope and Market Size
The global Prostate Cancer Diagnostics market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Prostate Cancer Diagnostics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region (country), by Type and by Application for the period 2015-2026.

Segment by Type, the Prostate Cancer Diagnostics market is segmented into
Tumor Biomarker Tests
Imaging
Biopsy
Other

Segment by Application, the Prostate Cancer Diagnostics market is segmented into
age < 55
age 55-75
age > 75

The Prostate Cancer Diagnostics market is analysed and market size information is provided by regions (countries). Segment by Application, the Prostate Cancer Diagnostics market is segmented into United States, Europe, China, Japan, Southeast Asia, India and Rest of World.
The report includes region-wise market size for the period 2015-2026. It also includes market size and forecast by players, by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.

Competitive Landscape

and Prostate Cancer Diagnostics Market Share Analysis
Prostate Cancer Diagnostics market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Prostate Cancer Diagnostics business, the date to enter into the Prostate Cancer Diagnostics market, Prostate Cancer Diagnostics product introduction, recent developments, etc.

The major vendors covered:
Genomic Health
Abbott
OPKO
Siemens Healthcare
DiaSorin
BioMeriux
Roche
MDx Health
Beckman Coulter
Myriad Genetics
Ambry Genetics